Salt Lake City, Utah--(September 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced that its stockholders authorized a reverse stock split of the Company's common stock. Following the annual stockholder meeting, the board of...
Kiora Pharmaceuticals Appoints Melissa Tosca as Executive Vice President of Finance
Salt Lake City, Utah--(September 13, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has appointed Melissa Tosca as Executive Vice President of Finance. Mrs. Tosca will join the executive management team and oversee finance, SEC reporting...
Kiora Pharmaceuticals Reports First Half 2022 Business Update and Financial Results
Salt Lake City, Utah--(August 12, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today is reporting financial results for the three and six months ended June 30, 2022."In the first half, we continued to advance three core programs...
Kiora Pharmaceuticals Issued US Patent Covering KIO-201 Technology in Combination with Antibiotics
Salt Lake City, Utah--(July 28, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") has been granted a U.S. patent covering hydrogel-based sustained release platforms, inclusive of KIO-201, which enable controlled release of antibiotics for...
Kiora Pharmaceuticals Announces Closing of $6.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
Salt Lake City, Utah--(July 26, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the closing of an underwritten public offering for gross proceeds of approximately $6.0 million, which includes full exercise of the...
Kiora Pharmaceuticals Announces Pricing of $5.2 Million Underwritten Public Offering
Salt Lake City, Utah--(July 22, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced the pricing of an underwritten public offering for gross proceeds of approximately $5.2 million prior to deducting underwriting discounts and...
Kiora Pharmaceuticals Announces First Patient Enrolled in Phase 2 Study Evaluating KIO-201 for Persistent Corneal Epithelial Defects
Salt Lake City, Utah--(July 5, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced enrolling the first patient as a part of a Phase 2 study evaluating KIO-201 topical eye drops in patients with Persistent Corneal Epithelial...
Kiora Pharmaceuticals Receives Clinical Trial Approval for First-in-Human Evaluation of KIO-301 to Restore Vision in Patients with Retinitis Pigmentosa
Salt Lake City, Utah--(June 27, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") received approval to initiate a first-in-human clinical trial for KIO-301, which is intended to restore lost vision in patients with Retinitis...
Kiora Pharmaceuticals Receives Nasdaq Notification of Non-Compliance with Listing Rule 5250(c)(1)
Salt Lake City, Utah--(May 31, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") today announced that on May 25, 2022, it received a letter from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") notifying the...
Kiora Pharmaceuticals Announces Presentation of KIO-101 Clinical Trial Data at the American Society of Cataract and Refractive Surgery 2022
Results support planned Phase 2 Trial to treat the Ocular Presentation of Rheumatoid Arthritis (OPRA)Salt Lake City, Utah--(April 25, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX), ("Kiora" or the "Company") announced that the full results of the KIO-101 Phase 1b...